Ziya Kalkan
Dicle, 21280, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 01, 2026
Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638.
Journal: Medicina (Kaunas, Lithuania)
Published: October 07, 2025
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Journal: Scientific reports
Published: March 19, 2025
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study.
Journal: Medicina (Kaunas, Lithuania)
Published: March 08, 2025
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.
Journal: Cancers
Published: October 24, 2024
Comparison of inflammatory indices in patients with metastatic non-small cell lung cancer.
Journal: Revista da Associacao Medica Brasileira (1992)
Published: July 07, 2024
Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors.
Journal: Postgraduate medicine
Published: February 08, 2024
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Journal: BMC cancer
Published: February 28, 2023
Last Updated: 09/26/2026